← All trials
NCT06132165
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2023
- Primary completion
- Oct 31, 2024
- Completion date
- Oct 31, 2024
- First posted
- Nov 15, 2023
- Last posted
- Nov 15, 2023
- Enrollment
- 30
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Harvard UniversityLead sponsor
- Harvard UniversityOverall official - principal investigator
- Harvard UniversityReponsible party - principal investigator
- Johns Hopkins UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.